Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
111 hedge funds and large institutions have $54.3M invested in Sanofi Contingent Value Rights in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $57M → $54.3M (-$2.79M)
3% less funds holding
Funds holding: 115 → 111 (-4)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$239K |
| 2 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$42.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.2K |
| 4 |
Goldman Sachs
New York
|
+$7.63K |
| 5 |
Bank of New York Mellon
New York
|
+$4.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$36.9K |
| 2 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$19K |
| 3 |
JP Morgan Chase
New York
|
-$8.86K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.05K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.04K |
GCVRZ Hedge Fund Activity: Q3 2017 in Review
111 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2017, worth a combined $54.3M — down 4.9% from $57M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GCVRZ and 5 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was Highbridge Capital Management, adding an estimated $239K. The largest seller was Bank of America, cutting an estimated $36.9K.
- 111 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2017, down from 115 in Q2 2017.
- Funds reported $54.3M of Sanofi Contingent Value Rights stock for Q3 2017, down 4.9% quarter-over-quarter.
- 5 funds opened new Sanofi Contingent Value Rights positions in Q3 2017 and 7 closed out, a net change of -2 holders.
- The largest Sanofi Contingent Value Rights buyer in Q3 2017 was Highbridge Capital Management, an estimated $239K added.
- The largest Sanofi Contingent Value Rights seller in Q3 2017 was Bank of America, an estimated $36.9K sold.
Based on aggregated 13F filings for Q3 2017.